Lataniston (Latanoprost)

Latanoprost is a synthetic prostaglandin F2α analogue that binds to FP receptors in the ciliary body. Activation of these receptors enhances uveoscleral outflow of aqueous humor, which reduces intra‑ocular pressure. By increasing this alternative drainage pathway, the drug helps control pressure that contributes to glaucoma progression.

The prescribed dose of Lataniston is determined by the treating ophthalmologist. Typically, one drop of the ophthalmic solution is instilled into the affected eye(s) once daily in the evening. Patients should follow the specific instructions provided by their healthcare professional and not alter the dosing schedule without consultation.

Safety of latanoprost in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and alternatives with their ophthalmologist.

To request Lataniston, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team then replies with pricing, availability, shipping details and any necessary import documentation.

Lataniston (latanoprost) belongs to the prostaglandin analogue class, which generally provides greater intra‑ocular pressure reduction with once‑daily dosing compared with beta‑blocker or carbonic anhydrase inhibitor drops. Its efficacy is comparable to other prostaglandin analogues such as bimatoprost, but individual response and side‑effect profiles may differ.

Lataniston should be stored at room temperature, below 25 °C, in the original bottle. Keep the container tightly closed, protect it from light and moisture, and avoid freezing. Do not refrigerate unless specifically instructed, and discard any solution that has been opened for longer than the indicated period after opening.

Lataniston is applied as an ophthalmic solution. The patient should wash hands, tilt the head back, and gently pull down the lower eyelid to form a pocket. One drop is placed into the conjunctival sac of the affected eye(s) once daily, preferably in the evening. Avoid touching the tip of the bottle to the eye or any surface.

While generally well tolerated, serious adverse events can occur. These include severe ocular inflammation, allergic reactions such as conjunctivitis, macular edema, and, rarely, vision loss. Patients should seek immediate medical attention if they experience persistent eye pain, redness, swelling, sudden vision changes, or signs of an allergic response.

Lataniston is contraindicated in patients with known hypersensitivity to latanoprost or any component of the formulation. It should also be avoided in individuals with active ocular infections, severe inflammation, or a history of intra‑ocular surgery within the past four weeks. Consultation with an eye care professional is essential before initiating therapy.